Do I need to exercise on Wegovy?

Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.

How fast do results show on GLP-1?

Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.

Why am I not losing weight on Wegovy?

Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.

Can I build muscle on a GLP-1?

Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.

Can GLP-1 help with PCOS?

Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.

Does GLP-1 work for type 1 diabetes?

No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

ICD-10 · E66

Obesity

Obesity is a chronic, relapsing disease defined by excess body fat that increases health risk. The medical threshold is BMI ≥30, or ≥27 with a weight-related comorbidity. GLP-1 medications Wegovy and Zepbound are FDA-approved for chronic weight management and produce 14–21% mean weight loss in clinical trials.

Medically reviewed by Dr. Jane Novak, MD, MPH on June 1, 2026

This is general health information, not medical advice. Talk to a licensed clinician about diagnosis and treatment options.

Overview

Obesity affects more than 40% of US adults and is associated with cardiovascular disease, type 2 diabetes, certain cancers, and reduced life expectancy. Modern obesity medicine recognizes it as a chronic disease — like hypertension — requiring long-term management rather than short-term dieting. FDA-approved GLP-1 receptor agonists for chronic weight management (Wegovy, Zepbound) are typically prescribed at BMI ≥30, or ≥27 with at least one weight-related comorbid condition. Trial data shows mean weight loss of 14.9% (semaglutide 2.4mg, STEP-1) to 20.9% (tirzepatide 15mg, SURMOUNT-1) at ~68 weeks.

Symptoms

BMI ≥30
Difficulty with physical activity
Shortness of breath
Joint pain
Sleep difficulties

Risk factors

Genetics
Sedentary lifestyle
High-calorie diet
Certain medications (steroids, antipsychotics)
Sleep deprivation
Endocrine disorders

Treatment options

Lifestyle modification
GLP-1 receptor agonists
Other anti-obesity medications
Bariatric surgery (BMI ≥35-40)

GLP-1 evidence for chronic weight management

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
Semaglutide 2.4 mg produces ~14-15% body-weight reduction at 68 weeks Source: NEJM, 2021 STEP-1 (n=1,961) and STEP-3 RCTs with converging results	AStrong evidence	STEP-1 (n=1,961) and STEP-3 RCTs with converging results
Tirzepatide 15 mg produces ~22% body-weight reduction at 72 weeks Source: NEJM, 2022 SURMOUNT-1 (n=2,539); class-leading effect size	AStrong evidence	SURMOUNT-1 (n=2,539); class-leading effect size
Weight regain is the norm if therapy is stopped Source: JAMA, 2023 STEP-1 extension and SURMOUNT-4: ~2/3 of lost weight regained within 12 months	AStrong evidence	STEP-1 extension and SURMOUNT-4: ~2/3 of lost weight regained within 12 months
Semaglutide reduces cardiovascular events in adults with obesity (no diabetes) Source: NEJM, 2023 SELECT (n=17,604), 20% MACE reduction	AStrong evidence	SELECT (n=17,604), 20% MACE reduction
Long-term GLP-1 use causes medullary thyroid cancer in humans Source: accessdata.fda.gov Rodent-only signal; no human cases attributed despite 10+ years post-approval	FNo evidence	Rodent-only signal; no human cases attributed despite 10+ years post-approval

Related GLP-1 medications

Ozempic

GLP-1 receptor agonist · ~$997.58/mo

View details

Wegovy

GLP-1 receptor agonist · ~$1349.02/mo

View details

Zepbound

GIP/GLP-1 dual receptor agonist · ~$1059.87/mo

View details

Not sure which medication is right for you? Our quiz matches you with providers based on state, insurance, and budget.

Take the GLP-1 quiz

Common questions readers ask

Do I need to exercise on Wegovy?: Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.
How fast do results show on GLP-1?: Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.
Why am I not losing weight on Wegovy?: Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.
Can I build muscle on a GLP-1?: Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.
Can GLP-1 help with PCOS?: Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.
Does GLP-1 work for type 1 diabetes?: No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

Sources

Pharmacological Management of Obesity — Endocrine Society Clinical Practice Guideline
Adult BMI categories — CDC

Was this page helpful?

Obesity

Medically reviewed by Dr. Jane Novak, MD, MPH on June 1, 2026

This is general health information, not medical advice. Talk to a licensed clinician about diagnosis and treatment options.

Overview

Symptoms

BMI ≥30
Difficulty with physical activity
Shortness of breath
Joint pain
Sleep difficulties

Risk factors

Genetics
Sedentary lifestyle
High-calorie diet
Certain medications (steroids, antipsychotics)
Sleep deprivation
Endocrine disorders

Treatment options

Lifestyle modification
GLP-1 receptor agonists
Other anti-obesity medications
Bariatric surgery (BMI ≥35-40)

GLP-1 evidence for chronic weight management

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
Semaglutide 2.4 mg produces ~14-15% body-weight reduction at 68 weeks Source: NEJM, 2021 STEP-1 (n=1,961) and STEP-3 RCTs with converging results	AStrong evidence	STEP-1 (n=1,961) and STEP-3 RCTs with converging results
Tirzepatide 15 mg produces ~22% body-weight reduction at 72 weeks Source: NEJM, 2022 SURMOUNT-1 (n=2,539); class-leading effect size	AStrong evidence	SURMOUNT-1 (n=2,539); class-leading effect size
Weight regain is the norm if therapy is stopped Source: JAMA, 2023 STEP-1 extension and SURMOUNT-4: ~2/3 of lost weight regained within 12 months	AStrong evidence	STEP-1 extension and SURMOUNT-4: ~2/3 of lost weight regained within 12 months
Semaglutide reduces cardiovascular events in adults with obesity (no diabetes) Source: NEJM, 2023 SELECT (n=17,604), 20% MACE reduction	AStrong evidence	SELECT (n=17,604), 20% MACE reduction
Long-term GLP-1 use causes medullary thyroid cancer in humans Source: accessdata.fda.gov Rodent-only signal; no human cases attributed despite 10+ years post-approval	FNo evidence	Rodent-only signal; no human cases attributed despite 10+ years post-approval

Common questions readers ask

Do I need to exercise on Wegovy?: Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.
How fast do results show on GLP-1?: Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.
Why am I not losing weight on Wegovy?: Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.
Can I build muscle on a GLP-1?: Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.
Can GLP-1 help with PCOS?: Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.
Does GLP-1 work for type 1 diabetes?: No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

Was this page helpful?